Lyra Therapeutics Inc (NASDAQ: LYRA) is -95.60% lower on its value in year-to-date trading and has touched a low of $0.24 and a high of $6.79 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LYRA stock was last observed hovering at around $0.25 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $0.23, the stock is -14.37% and -21.56% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.78 million and changing -6.04% at the moment leaves the stock -91.40% off its SMA200. LYRA registered -94.13% loss for a year compared to 6-month loss of -95.64%. The firm has a 50-day simple moving average (SMA 50) of $0.29244 and a 200-day simple moving average (SMA200) of $2.65673.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -19.90% gain in the last 1 month and extending the period to 3 months gives it a -15.33%, and is -4.60% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.37% over the week and 7.29% over the month.
Lyra Therapeutics Inc (LYRA) has around 88 employees, a market worth around $15.08M and $1.82M in sales. Profit margin for the company is -5570.88%. Distance from 52-week low is -4.04% and -96.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-159.78%).
The EPS is expected to shrink by -5.71% this year
71.0 institutions hold shares in Lyra Therapeutics Inc (LYRA), with institutional investors hold 59.65% of the company’s shares. The shares outstanding are 57.21M, and float is at 56.40M with Short Float at 5.57%. Institutions hold 59.26% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 12.76 million shares valued at $3.53 million. The investor’s holdings represent 19.9302 of the LYRA Shares outstanding. As of 2024-06-30, the second largest holder is CITADEL ADVISORS LLC with 4.77 million shares valued at $1.32 million to account for 7.4562 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.83 million shares representing 4.4211 and valued at over $0.78 million, while SAMSARA BIOCAPITAL, LLC holds 4.3434 of the shares totaling 2.78 million with a market value of $0.77 million.
Lyra Therapeutics Inc (LYRA) Insider Activity
The most recent transaction is an insider purchase by Waksal Harlan, the company’s Executive Chair. SEC filings show that Waksal Harlan bought 25,000 shares of the company’s common stock on Nov 10 ’23 at a price of $2.96 per share for a total of $74095.0. Following the purchase, the insider now owns 0.26 million shares.
